HK1014156A1 - Pharmaceutical compositions containing bactericidal permeability increasing protein and a surfactant - Google Patents
Pharmaceutical compositions containing bactericidal permeability increasing protein and a surfactantInfo
- Publication number
- HK1014156A1 HK1014156A1 HK98115456A HK98115456A HK1014156A1 HK 1014156 A1 HK1014156 A1 HK 1014156A1 HK 98115456 A HK98115456 A HK 98115456A HK 98115456 A HK98115456 A HK 98115456A HK 1014156 A1 HK1014156 A1 HK 1014156A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- bpi
- permeability increasing
- pharmaceutical compositions
- surfactant
- compositions containing
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- A61K38/1751—Bactericidal/permeability-increasing protein [BPI]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Gastroenterology & Hepatology (AREA)
- Oncology (AREA)
- Biochemistry (AREA)
- Communicable Diseases (AREA)
- Marine Sciences & Fisheries (AREA)
- Zoology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Dermatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US1236093A | 1993-02-02 | 1993-02-02 | |
PCT/US1994/001239 WO1994017819A1 (fr) | 1993-02-02 | 1994-02-02 | Compositions pharmaceutiques contenant une proteine bactericide ou accroissant la permeabilite, ainsi qu'un agent tensioactif |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1014156A1 true HK1014156A1 (en) | 1999-09-24 |
Family
ID=21754603
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK98115456A HK1014156A1 (en) | 1993-02-02 | 1998-12-24 | Pharmaceutical compositions containing bactericidal permeability increasing protein and a surfactant |
Country Status (13)
Country | Link |
---|---|
US (5) | US5488034A (fr) |
EP (1) | EP0682524B1 (fr) |
JP (2) | JP3946246B2 (fr) |
CN (1) | CN1163264C (fr) |
AT (1) | ATE206308T1 (fr) |
AU (1) | AU695125B2 (fr) |
CA (1) | CA2155005C (fr) |
DE (1) | DE69428521T2 (fr) |
DK (1) | DK0682524T3 (fr) |
ES (1) | ES2164098T3 (fr) |
HK (1) | HK1014156A1 (fr) |
PT (1) | PT682524E (fr) |
WO (1) | WO1994017819A1 (fr) |
Families Citing this family (75)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6277410B1 (en) | 1992-10-08 | 2001-08-21 | Supratek Pharma Inc. | Copolymer compositions for oral delivery |
US6153193A (en) * | 1993-04-28 | 2000-11-28 | Supratek Pharma Inc. | Compositions for targeting biological agents |
US6093391A (en) * | 1992-10-08 | 2000-07-25 | Supratek Pharma, Inc. | Peptide copolymer compositions |
US5420019A (en) * | 1993-02-02 | 1995-05-30 | Xoma Corporation | Stable bactericidal/permeability-increasing protein muteins |
US5488034A (en) | 1993-02-02 | 1996-01-30 | Xoma Corporation | Pharmaceutical composition comprising BPI proteins |
US6214789B1 (en) | 1993-03-12 | 2001-04-10 | Xoma Corporation | Treatment of mycobacterial diseases by administration of bactericidal/permeability-increasing protein products |
US5652332A (en) * | 1993-03-12 | 1997-07-29 | Xoma | Biologically active peptides from functional domains of bactericidal/permeability-increasing protein and uses thereof |
US5731415A (en) | 1993-06-17 | 1998-03-24 | Xoma Corporation | Lipopolysaccharide binding protein derivatives |
WO1995002414A1 (fr) * | 1993-07-14 | 1995-01-26 | Xoma Corporation | Methode permettant de potentialiser l'activite bactericide d'un produit contenant la proteine bpi par l'administration de produits contenant la proteine lbp |
US5770561A (en) * | 1993-07-14 | 1998-06-23 | Xoma Corporation | Method for potentiating BPI protein product bactericidal activity by administration of LBP protein products |
US6759203B1 (en) | 1993-09-22 | 2004-07-06 | Xoma Corporation | Method for quantifying BPI in body fluids |
DE69430823T2 (de) * | 1993-09-22 | 2003-02-20 | Xoma Technology Ltd | Verfahren zur behandlung von gram-negativen bakterien infektion durch verabreichung von bakterientötendem/durchlässigkeiterhöhendem (bpi) proteinprodukt und antibiotikum |
CN1133634A (zh) * | 1993-09-22 | 1996-10-16 | 爱克斯欧玛公司 | 定量体液中的bpi的方法 |
WO1995019180A1 (fr) * | 1994-01-14 | 1995-07-20 | Xoma Corporation | Procede et matieres de traitment d'infections bacteriennes a gram positif |
DE69526216T2 (de) * | 1994-01-14 | 2002-11-14 | Xoma Technology Ltd | Antifungaleverfahren und mitteln |
US5447913A (en) | 1994-03-11 | 1995-09-05 | Xoma Corporation | Therapeutic uses of bactericidal/permeability-increasing protein dimer products |
US5786324A (en) * | 1994-03-24 | 1998-07-28 | Regents Of The University Of Minnesota | Synthetic peptides with bactericidal activity and endotoxin neutralizing activity for gram negative bacteria and methods for their use |
US5830860A (en) * | 1994-03-24 | 1998-11-03 | Regents Of The University Of Minnesota | Peptides with bactericidal activity and endotoxin neutralizing activity for gram negative bacteria and methods for their use |
US5932544A (en) | 1994-05-31 | 1999-08-03 | Xoma Corporation | Bactericidal/permeability-increasing protein (BPI) compositions |
US6271203B1 (en) | 1994-07-07 | 2001-08-07 | Xoma Corporation | Anti-protozoan methods and materials |
US5646114A (en) * | 1994-07-11 | 1997-07-08 | Xoma Corporation | Anti-protozoan methods |
US6221959B1 (en) | 1994-11-18 | 2001-04-24 | Supratek Pharma, Inc. | Polynucleotide compositions |
US6353055B1 (en) | 1994-11-18 | 2002-03-05 | Supratek Pharma Inc. | Polynucleotide compositions |
US5912228A (en) * | 1995-01-13 | 1999-06-15 | Xoma Corporation | Therapeutic compositions comprising bactericidal/permeability-increasing (BPI) protein products |
US5494896A (en) * | 1995-03-31 | 1996-02-27 | Xoma Corporation | Method of treating conditions associated with burn injuries |
CA2227292A1 (fr) * | 1995-07-20 | 1997-02-06 | Xoma Corporation | Peptides antifongiques |
US5686414A (en) * | 1995-11-14 | 1997-11-11 | Xoma Corporation | Methods of treating conditions associated with corneal transplantation |
AU730307B2 (en) * | 1995-11-14 | 2001-03-01 | Xoma Corporation | Bactericidal permeability increasing protein (BPI) for treating conditions associated with corneal injury |
US5741779A (en) | 1996-05-10 | 1998-04-21 | Xoma Corporation | Antithrombotic materials and methods |
WO1997042966A1 (fr) * | 1996-05-10 | 1997-11-20 | Xoma Corporation | Applications therapeutiques de produits proteiques bactericides/augmentant la permeabilite (bpi) dans le cas de meningococcemies chez l'homme |
NZ332954A (en) * | 1996-05-23 | 2000-07-28 | Xoma Corp | Use of BPI protein products to treat humans with hemorrhage due to trauma |
EP0939766A2 (fr) | 1996-05-24 | 1999-09-08 | The Regents Of The University Of Minnesota | Synthese de peptides formant des feuillets beta solubles |
US5888973A (en) * | 1996-08-09 | 1999-03-30 | Xoma Corporation | Anti-chlamydial uses of BPI protein products |
AU6358898A (en) * | 1996-09-09 | 1998-04-17 | Alexander V Kabanov | Fluorinated copolymeric pharmaceutical adjuncts |
AU744918B2 (en) * | 1996-11-01 | 2002-03-07 | Xoma Corporation | Therapeutic uses of BPI protein products in cystic fibrosis patients |
US6482796B2 (en) * | 1996-11-01 | 2002-11-19 | Xoma Corporation | Therapeutic uses of N-terminal BPI protein products in ANCA-positive patients |
US20030190307A1 (en) | 1996-12-24 | 2003-10-09 | Biogen, Inc. | Stable liquid interferon formulations |
US6093573A (en) * | 1997-06-20 | 2000-07-25 | Xoma | Three-dimensional structure of bactericidal/permeability-increasing protein (BPI) |
FR2764800B1 (fr) * | 1997-06-23 | 1999-09-10 | Sanofi Sa | Composition pharmaceutique solide contenant des derives de benzofuranne |
US5990082A (en) | 1997-10-22 | 1999-11-23 | Xoma Corporation | Uses of lipopolysaccharide binding protein |
US6013631A (en) * | 1998-06-19 | 2000-01-11 | Xoma Corporation | Bactericidal/permeability-increasing protein (BPI) deletion analogs |
US20030166525A1 (en) * | 1998-07-23 | 2003-09-04 | Hoffmann James Arthur | FSH Formulation |
WO2000062795A2 (fr) * | 1999-04-21 | 2000-10-26 | The Government Of The United States Of America, Represented By The Secretary, Department Of Healt H And Human Services The National Institutes Of Health | Uteroglobine utilisee dans le traitement des troubles auto-immunes lies a l'iga |
US6413537B1 (en) | 2000-03-10 | 2002-07-02 | Wisconsin Alumni Research Foundation | Nystatin formulation having reduced toxicity |
US7256180B2 (en) | 2000-04-28 | 2007-08-14 | Supratek Pharma Inc. | Compositions and methods for inducing activation of dendritic cells |
AU2002335815A1 (en) * | 2001-10-16 | 2003-04-28 | Rxkinetix, Inc. | High-concentration protein formulations and method of manufacture |
EP1572719A4 (fr) | 2002-02-20 | 2007-11-14 | Univ Minnesota | Mimetiques peptidiques partiels et procedes associes |
WO2004007520A2 (fr) * | 2002-07-12 | 2004-01-22 | Medarex, Inc. | Procedes et compositions visant a prevenir la degradation oxydative de proteines |
EP1567191B1 (fr) * | 2002-11-26 | 2010-09-08 | Eurocine Vaccines AB | Nouvel adjuvant a base d'amine |
KR101235507B1 (ko) * | 2003-02-28 | 2013-02-20 | 추가이 세이야쿠 가부시키가이샤 | 단백질을 함유하는 안정화 제제 |
KR101105486B1 (ko) * | 2003-04-02 | 2012-01-13 | 아레스 트레이딩 에스.에이. | Fsh 및 lh과 비이온성 계면활성제의 액상 약제학적 제제 |
US7838721B2 (en) * | 2003-04-09 | 2010-11-23 | Paragon Trade Brands, Llc | Disposable articles using high column AUL superabsorbents |
CA2526099C (fr) * | 2003-06-20 | 2013-02-05 | Ares Trading Sa | Formulations lyophilisees a base de fsh/lh |
US8377459B2 (en) * | 2003-07-09 | 2013-02-19 | The Procter & Gamble Company | Composition for wet wipes that enhances the efficacy of cleansing while being gentle to the skin |
US20050220881A1 (en) * | 2003-10-10 | 2005-10-06 | Bvm Holding Co. | Pharmaceutical composition |
US7150995B2 (en) * | 2004-01-16 | 2006-12-19 | Metrika, Inc. | Methods and systems for point of care bodily fluid analysis |
EP1776137B1 (fr) * | 2004-08-04 | 2014-11-26 | Ipsen Biopharm Limited | Composition pharmaceutique contenant de la neurotoxine botulique a2 |
EP1778279B1 (fr) * | 2004-08-04 | 2014-12-03 | Ipsen Biopharm Limited | Composition pharmaceutique contenant la neurotoxine botulique a2 |
US20060173428A1 (en) * | 2005-02-02 | 2006-08-03 | Acors Deanna M | Absorbent article with logically correlated image and textual graphics |
EP1885393A4 (fr) | 2005-05-18 | 2011-03-02 | Childrens Hosp & Res Ct Oak | Procédés et compositions permettant l'immunisation contre les infections à chlamydia |
CU23432B6 (es) * | 2005-11-02 | 2009-10-16 | Ct Ingenieria Genetica Biotech | Formulaciones estabilizadas que contienen a los interferones gamma y alfa en proporciones potenciadoras |
WO2009021173A1 (fr) * | 2007-08-08 | 2009-02-12 | Advanced Liquid Logic, Inc. | Utilisation d'additifs pour améliorer le déplacement de gouttelettes |
JP5387850B2 (ja) * | 2007-09-12 | 2014-01-15 | Jsr株式会社 | タンパク安定化剤およびその製造方法、タンパク安定化剤の使用方法、ならびにタンパク安定化方法 |
PT2310412T (pt) | 2008-06-20 | 2018-05-28 | Novartis Ag | Imunoglobulinas com agregação reduzida |
MX338775B (es) | 2009-06-04 | 2016-05-02 | Novartis Ag | Metodos para identificacion de sitios para conjugacion de igg. |
PT2585104T (pt) * | 2010-06-25 | 2019-10-30 | Shire Human Genetic Therapies | Métodos e composições de arilsulfatase a para a administração no snc |
US11246915B2 (en) | 2010-09-15 | 2022-02-15 | Applied Molecular Transport Inc. | Cholix toxin-derived fusion molecules for oral delivery of biologically active cargo |
US9090691B2 (en) | 2010-09-15 | 2015-07-28 | Applied Molecular Transport Llc | Systems and methods of delivery of bioactive agents using bacterial toxin-derived transport sequences |
GB201116271D0 (en) | 2011-09-21 | 2011-11-02 | Univ Cardiff | Dispersion anaesthetic device |
CN106470707A (zh) | 2014-05-07 | 2017-03-01 | 应用分子运输有限责任公司 | 用于口服递送生物活性货物的cholix毒素衍生的融合分子 |
WO2019173787A1 (fr) | 2018-03-08 | 2019-09-12 | Applied Molecular Transport Inc. | Constructions d'administration dérivées de toxines pour administration orale |
EP3762009B1 (fr) | 2018-03-08 | 2022-05-11 | Applied Molecular Transport Inc. | Constructions d'administration dérivées de toxines pour administration orale |
MX2022001975A (es) | 2019-08-16 | 2022-03-11 | Applied Molecular Transport Inc | Composiciones, formulaciones y produccion y purificacion de interleucinas. |
JP2023517511A (ja) * | 2020-03-18 | 2023-04-26 | ジーアイ イノベーション, インコーポレイテッド | Il-2タンパク質とcd80タンパク質を含む融合タンパク質製剤 |
JP2022151814A (ja) * | 2021-03-24 | 2022-10-07 | Jcrファーマ株式会社 | 安定な水性医薬組成物又は凍結乾燥医薬組成物 |
Family Cites Families (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3839314A (en) * | 1971-06-29 | 1974-10-01 | Baxter Laboratories Inc | Clarification of blood serum and plasma using block copolymers of ethylene oxide and polyoxypropylene |
US4478829A (en) * | 1983-04-28 | 1984-10-23 | Armour Pharmaceutical Company | Pharmaceutical preparation containing purified fibronectin |
US4933179A (en) * | 1983-08-22 | 1990-06-12 | Syntex (U.S.A.) Inc. | Feline leukemia virus antigen vaccines |
DE3406497A1 (de) * | 1984-02-23 | 1985-09-05 | Mueller Bernhard Willi Werner | Hochdisperse pharmazeutische mehrkomponentensysteme und verfahren zu ihrer herstellung |
US5234683A (en) * | 1985-06-18 | 1993-08-10 | Emory University | Method of stimulating the immune system |
US5030448A (en) * | 1986-05-15 | 1991-07-09 | Emory University | Method of delivering drugs to damaged or diseased tissue |
US5039520A (en) * | 1986-05-15 | 1991-08-13 | Emory University | Plasma extender |
US5182106A (en) * | 1986-05-15 | 1993-01-26 | Emory University | Method for treating hypothermia |
US5071649A (en) * | 1986-05-15 | 1991-12-10 | Emory University | Method of preventing blockage in catheters |
US5152979A (en) * | 1986-05-15 | 1992-10-06 | Emory University | Method for treating vascular obstructions caused by abnormal cells |
US5041288A (en) * | 1986-05-15 | 1991-08-20 | Emory University | Method of treating tissue damaged by reperfusion injury |
FR2608988B1 (fr) * | 1986-12-31 | 1991-01-11 | Centre Nat Rech Scient | Procede de preparation de systemes colloidaux dispersibles d'une substance, sous forme de nanoparticules |
FR2634397B2 (fr) * | 1986-12-31 | 1991-04-19 | Centre Nat Rech Scient | Procede de preparation de systemes colloidaux dispersibles d'une proteine sous forme de nanoparticules |
EP0305470B1 (fr) * | 1987-02-20 | 1992-11-11 | Emory University | Composes anti-infectieux et procede d'utilisation |
US5198541A (en) * | 1987-08-11 | 1993-03-30 | New York University | Dna encoding bactericidal/permeability-increasing proteins |
DE3853918T2 (de) * | 1987-08-11 | 1996-02-08 | Univ New York | Biologisch aktive bakterientötende/durchlässigkeitserhöhende proteinfragmente. |
FR2630115B1 (fr) * | 1988-04-14 | 1994-10-28 | Merieux Inst | Procede de stabilisation des solutions d'albumine humaine et solution obtenue |
US5096885A (en) * | 1988-04-15 | 1992-03-17 | Genentech, Inc. | Human growth hormone formulation |
JPH02107163A (ja) * | 1988-10-15 | 1990-04-19 | Suntory Ltd | 新規なゲル状食品の製造方法 |
US5089274A (en) * | 1989-02-14 | 1992-02-18 | Incyte Pharmaceuticals, Inc. | Use of bactericidal/permeability increasing protein or biologically active analogs thereof to treat endotoxin-related disorders |
US5334584A (en) * | 1989-02-14 | 1994-08-02 | Incyte Pharamaceuticals, Inc. | Recombinant, non-glycosylated bpi protein and uses thereof |
US5171739A (en) * | 1989-02-14 | 1992-12-15 | Incyte Pharmaceuticals, Inc. | Treatment of endotoxin-associated shock and preventation thereof using a BPI protein |
US5308834A (en) * | 1989-02-14 | 1994-05-03 | Incyte Pharmaceuticals, Inc. | Treatment of endotoxin-associated shock and prevention thereof using a BPI protein |
US5234912A (en) * | 1989-02-14 | 1993-08-10 | Incyte Pharmaceuticals, Inc. | Pharmaceutical compositions comprising recombinant BPI proteins and a lipid carrier and uses thereof |
US4997664A (en) * | 1989-09-05 | 1991-03-05 | Bryan Foods, Inc. | Method for packaging food products |
DE69128968T2 (de) * | 1990-12-03 | 1998-10-08 | Univ New York | Biologisch aktive bakterizide/permeabilitätserhöhende proteinbruchstücke |
IE920860A1 (en) * | 1991-03-19 | 1992-09-23 | Cytrx Corp | Polyoxypropylene/polyoxyethylene copolymers with improved¹biological activity |
US5234908A (en) * | 1991-04-12 | 1993-08-10 | Creative Biomolecules, Inc. | Method of treating gastrointestinal ulcers with platelet derived growth factor |
AU2872792A (en) * | 1991-09-26 | 1993-04-27 | Incyte Pharmaceuticals, Inc. | A new form of liposaccharide binding protein (lbp) |
ES2132239T3 (es) * | 1992-05-19 | 1999-08-16 | Xoma Corp | Metodos mejorados para la preparacion de proteinas de union a endotoxinas. |
WO1993023434A2 (fr) * | 1992-05-19 | 1993-11-25 | Xoma Corporation | Proteines de fusion de l'immunoglobuline bactericides augmentant la permeabilite |
US5488034A (en) * | 1993-02-02 | 1996-01-30 | Xoma Corporation | Pharmaceutical composition comprising BPI proteins |
US5348942A (en) * | 1993-03-12 | 1994-09-20 | Xoma Corporation | Therapeutic uses of bactericidal/permeability increasing protein products |
-
1994
- 1994-02-02 US US08/190,869 patent/US5488034A/en not_active Expired - Lifetime
- 1994-02-02 AT AT94907963T patent/ATE206308T1/de not_active IP Right Cessation
- 1994-02-02 DE DE69428521T patent/DE69428521T2/de not_active Expired - Fee Related
- 1994-02-02 ES ES94907963T patent/ES2164098T3/es not_active Expired - Lifetime
- 1994-02-02 CN CNB941913554A patent/CN1163264C/zh not_active Expired - Fee Related
- 1994-02-02 AU AU61330/94A patent/AU695125B2/en not_active Ceased
- 1994-02-02 EP EP94907963A patent/EP0682524B1/fr not_active Expired - Lifetime
- 1994-02-02 JP JP51821394A patent/JP3946246B2/ja not_active Expired - Fee Related
- 1994-02-02 DK DK94907963T patent/DK0682524T3/da active
- 1994-02-02 CA CA002155005A patent/CA2155005C/fr not_active Expired - Fee Related
- 1994-02-02 WO PCT/US1994/001239 patent/WO1994017819A1/fr active IP Right Grant
- 1994-02-02 PT PT94907963T patent/PT682524E/pt unknown
-
1995
- 1995-06-07 US US08/472,995 patent/US5696090A/en not_active Expired - Fee Related
-
1997
- 1997-12-08 US US08/986,413 patent/US5955427A/en not_active Expired - Fee Related
-
1998
- 1998-12-24 HK HK98115456A patent/HK1014156A1/xx not_active IP Right Cessation
-
1999
- 1999-05-17 US US09/313,525 patent/US6066620A/en not_active Expired - Lifetime
-
2000
- 2000-02-11 US US09/502,356 patent/US6255284B1/en not_active Expired - Fee Related
-
2005
- 2005-02-25 JP JP2005052149A patent/JP2005145986A/ja not_active Withdrawn
Also Published As
Publication number | Publication date |
---|---|
EP0682524B1 (fr) | 2001-10-04 |
US6066620A (en) | 2000-05-23 |
JP3946246B2 (ja) | 2007-07-18 |
EP0682524A1 (fr) | 1995-11-22 |
CA2155005A1 (fr) | 1994-08-18 |
CA2155005C (fr) | 1999-04-06 |
JPH10513433A (ja) | 1998-12-22 |
ES2164098T3 (es) | 2002-02-16 |
US5955427A (en) | 1999-09-21 |
US5488034A (en) | 1996-01-30 |
PT682524E (pt) | 2002-03-28 |
CN1163264C (zh) | 2004-08-25 |
US5696090A (en) | 1997-12-09 |
CN1127992A (zh) | 1996-07-31 |
AU6133094A (en) | 1994-08-29 |
DE69428521D1 (de) | 2001-11-08 |
DE69428521T2 (de) | 2002-05-23 |
AU695125B2 (en) | 1998-08-06 |
JP2005145986A (ja) | 2005-06-09 |
ATE206308T1 (de) | 2001-10-15 |
US6255284B1 (en) | 2001-07-03 |
WO1994017819A1 (fr) | 1994-08-18 |
DK0682524T3 (da) | 2002-01-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1014156A1 (en) | Pharmaceutical compositions containing bactericidal permeability increasing protein and a surfactant | |
CA2113995A1 (fr) | Utilisation d'acide gentisique ou d'alcool gentisique pour la stabilisation de peptides et de proteines radiomarques | |
NL300212I1 (nl) | ASP-B28 insulinekristallen. | |
DE69312947D1 (de) | Proteinhaftige arzneimittel mit verzögerter wirkstoffabgabe | |
IL106750A0 (en) | Peg interferon conjugates | |
MXPA00010241A (es) | Composicion farmaceutica que comprende el factor viii y liposomas neutrales.. | |
DE69417252T2 (de) | Verbesserte immunogene zusammensetzung gegen mensliches gastrin 17 | |
DE3875108D1 (de) | Physiologisch aktives polypeptid und pharmazeutische komposition. | |
EP0422125A4 (en) | Platelet blocking peptides | |
GR3034309T3 (en) | IFN--g(b) LIQUID FORMULATIONS | |
BR0211186A (pt) | peptìdeos e uso dos mesmos no escurecimento da pele | |
IL132201A0 (en) | Stabilized human papillomavirus formulations | |
ATE103776T1 (de) | Neue n-(sulfomethyl)-n'-arylharnstoffe. | |
CA2071757A1 (fr) | Compositions pour implant contenant une proteine, un peptide ou un polypeptide biologiquement actif | |
WO1999033989A3 (fr) | Mutants rantes et leurs applications therapeutiques | |
CA2235805A1 (fr) | Agent antitumoral | |
CA2247998A1 (fr) | Fragments de recepteur du complement de type 1 et leurs utilisations | |
CA2153071A1 (fr) | Derives de calcitonines | |
AU3975693A (en) | Recombinant active forms of ECEF, proteins that associate therewith, and uses thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PF | Patent in force | ||
PC | Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee) |
Effective date: 20090202 |